1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
Mobius Therapeutics Logo

Mobius Therapeutics™ Announces Assignment of HCPCS Code for Mitosol®

Centers for Medicare and Medicaid Services Assigns Code for Billing Medicare, Private Insurance

PRLog - Nov. 8, 2012 - (ST. LOUIS) — Mobius Therapeutics, LLC announced today the Centers for Medicare and Medicaid Services (CMS) has assigned a product-specific Healthcare Common Procedures Coding System (HCPCS) code for Mitosol® (mitomycin for solution) 0.2mg/vial, Kit for Ophthalmic Use.  Mitosol is used as an adjunct to ab externo glaucoma surgery.   The new J-code, J7315, becomes effective on January 1, 2013.  

"This is an important milestone for Mobius Therapeutics, and we are very pleased that CMS has issued a J-code for Mitosol®," said Ed Timm, Chief Executive Officer and Founder of Mobius Therapeutics, LLC.  "While it may take up to three months for the J-code to be loaded into the entire payer system, the J-code facilitates more rapid reimbursement for providers. Mitosol is manufactured under cGMP controls and provides assured dosing concentration with consistent potency and sterility.  In light of the on-going concerns related to the sterility and quality assurance of sterile filled medications, Mitosol’s quality manufacturing and convenience helps providers and patients with peace of mind.”

J-codes are part of the Healthcare Common Procedure Coding System (HCPCS), and used by providers to identify medical products to facilitate reimbursement.

About Mobius Therapeutics, LLC:

Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions.  Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery.  The glaucoma indication is in active commercialization; the pterygium and refractive indications are awaiting approval by the Food and Drug Administration.  Mobius is housed within the Center for Emerging Technologies in St. Louis, Missouri.

--- End ---

Click to Share

Contact Email:
***@vandivergroup.com Email Verified
Source:Mobius Therapeutics
Country:United States
Tags:Mobius Therapeutics, mitosol, j-codes
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “


Trending News...

  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
Click to Share